middle.news
EVE Advances Libbo Trial and Apixaban Solubility with New CEO
12:43pm on Friday 7th of August, 2026 AEST
•
Healthcare
Read Story
EVE Advances Libbo Trial and Apixaban Solubility with New CEO
12:43pm on Friday 7th of August, 2026 AEST
Key Points
Libbo pilot clinical study protocol finalised
Pilot dosing delayed to Q4 2026, data expected early 2027
Apixaban solubility improved over 80-fold using proprietary tech
Ben Rohr appointed CEO focusing on commercial execution
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Eve Health (ASX:EVE)
OPEN ARTICLE